Trial Profile
A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Remtolumab (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 31 May 2018 Results published in the Arthritis and Rheumatology
- 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2015 Planned number of patients changed from 160 to 225 as reported by ClinicalTrials.gov record and European Clinical Trials Database record.